Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Naratriptan
Drug ID BADD_D01535
Description Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine attacks with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC02
DrugBank ID DB00952
KEGG ID D08255
MeSH ID C106783
PubChem ID 4440
TTD Drug ID D0T3KI
NDC Product Code 69452-340; 69452-341; 23155-054; 42043-130; 42043-131; 23155-055; 50090-6162; 0054-0278; 0054-0279
UNII QX3KXL1ZA2
Synonyms naratriptan | N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide | GR 85548A | naratriptan hydrochloride | N-methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride | 1H-indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride | Naramig | Amerge | Colatan
Chemical Information
Molecular Formula C17H25N3O2S
CAS Registry Number 121679-13-8
SMILES CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Electrocardiogram PR prolongation13.14.05.012--Not Available
Throat lesion22.12.03.030--Not Available
Phonophobia19.06.03.003; 04.03.01.008--Not Available
Haemorrhage24.07.01.002--Not Available
Haemorrhage urinary tract24.07.01.007; 20.02.03.005--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Blood bilirubin abnormal13.03.04.016--Not Available
Spinal cord infarction17.08.01.075; 24.04.06.0180.005050%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Urine output increased13.13.03.002--Not Available
Cardiac disorder02.11.01.003--Not Available
Female reproductive tract carcinoma in situ21.10.02.003; 16.12.03.002--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Ischaemia24.04.02.004--Not Available
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Cranial nerve paralysis17.04.01.002--Not Available
Hyperlipidaemia14.08.03.001--
Neck injury12.01.09.001--Not Available
Cystitis noninfective20.03.02.001--
Regurgitation07.01.07.004--Not Available
Upper airway obstruction22.12.03.032--Not Available
Medication overuse headache17.14.01.015; 08.06.02.015--Not Available
Rheumatic disorder15.03.04.018; 10.02.01.048--Not Available
Noninfective sialoadenitis07.06.04.003--Not Available
Persistent depressive disorder19.15.01.006--Not Available
Therapy non-responder08.06.01.0630.007407%Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 8th Page    First    Pre   8    Total 8 Pages